You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Murine peripheral blood prognostic biomarkers for tumor survival following combination aCTLA-4 and aPD-1 treatment
  1. Ian Hilgart-Martiszus1,
  2. Michael McNamara1,2 and
  3. William Redmond1,2
  1. Aff1 grid.415286.c0000 0004 0463 5556Earle A Chiles Research Institute Portland OR USA
  2. Aff2 grid.415337.7Providence Cancer Center Portland OR USA

https://doi.org/10.1186/2051-1426-3-S2-P91

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Immune checkpoint inhibitors, particularly those targeting CTLA-4 and PD-1, are transforming the way cancer is treated. However, these therapies do not benefit all patients and frequently cause significant immune-related adverse events. Therefore, prognostic biomarkers that identify positively-responding patients, early in the course of therapy, are essential for guiding treatment decisions and improving patient outcomes.

    Methods

    In this study, we present evidence that shortly after initiating combination PD-1/CTLA-4 blockade, there is a transient increase in the frequency of pro-inflammatory and cytotoxic lymphocytes in peripheral blood, and the dynamics of this shift correlate with survival outcomes in multiple murine models.

    Results

    Specifically, we observed that 1) the relative frequency of cytotoxic CD8 T cells among peripheral lymphocytes and 2) the pro-inflammatory capacity of peripheral lymphocytes are both predictive for outcomes at an early time point. Surprisingly, robust correlations between peripheral lymphocyte markers and outcomes were limited to CD8 T cell populations. In general, the expression of potential biomarkers on peripheral CD4 T cells, including ICOS and FoxP3, were poorly correlated with outcomes in this study.

    Conclusions

    Overall, these findings suggest that elements of the near-term peripheral immune response to dual anti-PD-1/anti-CTLA-4 therapy associated with cytotoxic lymphocyte function may provide unique prognostic biomarkers for therapeutic outcomes.

    Figure